Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

doi:10.1001/jamaoncol.2016.5751

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

JAMA oncology - 1 May 2017

Joensuu Heikki, Wardelmann Eva, Sihto Harri, Eriksson Mikael, Sundby Hall Kirsten, Reichardt Annette, Hartmann Jörg T, Pink Daniel, Cameron Silke, Hohenberger Peter, Al-Batran Salah-Eddin, Schlemmer Marcus, Bauer Sebastian, Nilsson Bengt, Kallio Raija, Junnila Jouni, Vehtari Aki, Reichardt Peter

Abstract excerpt

IMPORTANCE: Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PDGFRA) mutations. OBJECTIVE: To investigate the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated with surgery and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Kaplan-Meier Estimate

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 28334365
DOI: 10.1001/jamaoncol.2016.5751
PMCID: PMC5470395

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.PMID 28334365Read ↗

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Semantic proximity Read ↗

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.Semantic proximity Read ↗

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.Semantic proximity Read ↗

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.Semantic proximity Read ↗

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Semantic proximity Read ↗

KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.Semantic proximity Read ↗

Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.Semantic proximity Read ↗

Results on prognostic value of mutations in localized gastrointestinal stromal tumors (GIST) in one single center.Semantic proximity Read ↗

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GISTSemantic proximity Read ↗

Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.Semantic proximity Read ↗

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.Semantic proximity Read ↗

Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.